Your Health, We Care
Alpelisib is indicated in combination with fulvestrant for the treatment of postmenopausal women, and men, with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, advanced or metastatic breast cancer as detected by an FDA-approved test following progression on or after an endocrine-based regimen.
from FDA,2022.11
By specifically inhibiting PIK3CA mutations, Apelis provides a novel therapeutic···【more】
Release date：2024-08-23Recommended：99
Alpelisib fills a gap in the treatment of HR/HER2- breast cancer, particularly i···【more】
Release date：2024-08-23Recommended：96
For patients with advanced HR/HER2- breast cancer, the combination of Alpelisib ···【more】
Release date：2024-08-23Recommended：92
